Literature DB >> 14623619

The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Hashem B El-Serag1, Jessica A Davila, Nancy J Petersen, Katherine A McGlynn.   

Abstract

BACKGROUND: The incidence of hepatocellular carcinoma was reported to be increasing in the United States. However, alternate explanations were diagnostic or reclassification bias and changes in the demographic features of the general population.
OBJECTIVE: To examine the temporal trends in the incidence of hepatocellular carcinoma.
DESIGN: Retrospective cohort study.
SETTING: Information collected by population-based registries of the Surveillance, Epidemiology, and End Results (SEER) program. PATIENTS: Persons given a diagnosis of hepatocellular carcinoma between 1975 and 1998. MEASUREMENTS: Linear Poisson multivariate regression model, controlling for differences in age, sex, race or ethnicity, and geographic region among patients with hepatocellular carcinoma and in the underlying population.
RESULTS: The overall age-adjusted incidence rates of hepatocellular carcinoma increased from 1.4 per 100 000 in 1975 to 1977 to 3.0 per 100 000 in 1996 to 1998. There was a 25% increase during the last 3 years of the study compared with the preceding 3 years (1993 to 1995). The increase affected most age groups above 40 years, with the greatest increase in the 45- to 49-year-old age group. White men had the greatest increase (31%) in the last time period (1996 to 1998) compared with 1993 to 1995. The Poisson regression model confirmed an almost 2-fold increase in the incidence rate ratio for hepatocellular carcinoma between 1975 to 1978 and 1996 to 1998.
CONCLUSIONS: The incidence of hepatocellular carcinoma continues to increase rapidly in the United States, with rates increasing the fastest in white men 45 to 54 years of age. These findings are consistent with a true increase and could be explained by consequences of hepatitis C virus acquired during the 1960s and 1970s.

Entities:  

Mesh:

Year:  2003        PMID: 14623619     DOI: 10.7326/0003-4819-139-10-200311180-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  248 in total

1.  Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Neil Mehta; Francis Y Yao; John P Roberts
Journal:  Clin Transplant       Date:  2014-12-01       Impact factor: 2.863

2.  Viral hepatitis in Hawai'i--differing perspectives.

Authors:  Alan D Tice; Michael Bannan; Kay Bauman; Tarquin Collis; Alba Hall; William Haning; Shoshana Hannemann; C Bradley Hare; Joseph Humphry; Robert Jao; Carroll Leevy; Heather Lusk; Edward Ochoa; Neal Palafox; Nancy Withers; Kenneth Akinaka
Journal:  Hawaii Med J       Date:  2010-04

3.  Prevention of post liver transplant HBV recurrence.

Authors:  Geoffrey W McCaughan
Journal:  Hepatol Int       Date:  2011-08-10       Impact factor: 6.047

Review 4.  Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma.

Authors:  William C Palmer; Tushar Patel
Journal:  J Hepatol       Date:  2012-03-13       Impact factor: 25.083

5.  Needle track seeding following percutaneous procedures for hepatocellular carcinoma.

Authors:  Giuseppe Cabibbo; Antonio Craxì
Journal:  World J Hepatol       Date:  2009-10-31

6.  Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury.

Authors:  Nikhil Bhagat; Diane K Reyes; Mingde Lin; Ihab Kamel; Timothy M Pawlik; Constantine Frangakis; J F Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2012-06-22       Impact factor: 2.740

7.  Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis.

Authors:  Hiroshi Sogawa; Brian Shrager; Ghalib Jibara; Parissa Tabrizian; Sasan Roayaie; Myron Schwartz
Journal:  HPB (Oxford)       Date:  2012-08-30       Impact factor: 3.647

8.  A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.

Authors:  Masao Omata; Haruhiko Yoshida; Joji Toyota; Eiichi Tomita; Shuhei Nishiguchi; Norio Hayashi; Shiro Iino; Isao Makino; Kiwamu Okita; Gotaro Toda; Kyuichi Tanikawa; Hiromitsu Kumada
Journal:  Gut       Date:  2007-06-15       Impact factor: 23.059

Review 9.  Irreversible electroporation of hepatic malignancy.

Authors:  Govindarajan Narayanan; Tatiana Froud; Rekhaben Suthar; Katuska Barbery
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 10.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.